Cardiac risk of noncardiac surgery after percutaneous coronary intervention with drug-eluting stents

被引:164
|
作者
Rabbitts, Jennifer A. [1 ]
Nuttall, Gregory A. [1 ]
Brown, Michael J. [1 ]
Hanson, Andrew C. [4 ]
Oliver, William C. [1 ]
Holmes, David R. [2 ,3 ]
Rihal, Charanjit S. [2 ,3 ]
机构
[1] Mayo Clin, Dept Anesthesiol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Med, Rochester, MN 55905 USA
[3] Mayo Clin, Coll Med, Rochester, MN 55905 USA
[4] Mayo Clin, Div Biostat, Rochester, MN 55905 USA
关键词
D O I
10.1097/ALN.0b013e318186de1c
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: The American College of Cardiology released a scientific advisory that included a recommendation to delay elective of noncardiac surgery (NCS) for 1 yr after percutaneous coronary intervention (PCI) with a drug-eluting stent (DES). Methods: This single-center, retrospective study examined the risk for complications of NCS performed within 2 yr after DES placement and examined whether this risk changed based on the time between procedures. The primary endpoint was major adverse cardiac events (MACEs) during the hospitalization for NCS. Bleeding events were analyzed as a secondary endpoint. Results: From April 22, 2003, to December 31, 2006, a total of 520 patients underwent NCS within 2 yr after PCI with a DES at Mayo Clinic. The majority, 84%, of the DES placed were Cypher stents. The frequency of MACE was not found to be significantly associated with the time between PCI and NCS (rate of MACEs 6.4, 5.7, 5.9, and 3.3% at 0-90, 91-180, 181-365, and 366-730 days after PCI with DES, respective]),; P = 0.727 for comparison across groups). Characteristics found to he associated with MACEs in univariate analysis were advanced age (P = 0.031), emergent NCS (P = 0.006), shock at time of PCI (P = 0.035), previous history of myocardial infarction (P = 0.046), and continuation of a thienopyridine (ticlopidine or clopidogrel) into the preoperative period (P = 0.040). The rate of transfusion did not seem to be associated with antiplatelet therapy use. Conclusions: The risk of MACEs with NCS after DES placement was not significantly associated with time from stenting to surgery, but observed rates of MACEs were lowest after 1 yr.
引用
收藏
页码:596 / 604
页数:9
相关论文
共 50 条
  • [1] Cardiac Risk of Noncardiac Surgery After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents
    Smith, Bradford B.
    Warner, Matthew A.
    Warner, Nafisseh S.
    Hanson, Andrew C.
    Smith, Mark M.
    Rihal, Charanjit S.
    Gulati, Rajiv
    Bell, Malcolm R.
    Nuttall, Gregory A.
    ANESTHESIA AND ANALGESIA, 2019, 128 (04): : 621 - 628
  • [2] Risk of non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents
    Park, Sun-Kyung
    Jung, Dhong Eun
    Jung, Sung Ae
    Kim, Won Ho
    Bahk, Jae-Hyon
    SCIENTIFIC REPORTS, 2017, 7
  • [3] Risk of non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents
    Sun-Kyung Park
    Dhong Eun Jung
    Sung Ae Jung
    Won Ho Kim
    Jae-Hyon Bahk
    Scientific Reports, 7
  • [4] The optimal timing for non-cardiac surgery after percutaneous coronary intervention with drug-eluting stents
    Choi, Cheol Ung
    Rha, Seung-Woon
    Jin, Zhe
    Chen, Kang-yin
    Minami, Yoshiyasu
    Kim, Ji Hoon
    Na, Jin Oh
    Suh, Soon Yong
    Kim, Jin Won
    Kim, Eung Ju
    Park, Chang Gyu
    Seo, Hong Seog
    Oh, Dong Joo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 139 (03) : 313 - 316
  • [5] Drug-Eluting Stents and Noncardiac Surgery
    Bolsin, Stephen N.
    Gillett, Jessica
    CHEST, 2014, 145 (05) : 1174 - 1174
  • [6] Cardiology - Percutaneous coronary intervention and drug-eluting stents
    Yang, YM
    Moussa, I
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 172 (03) : 323 - 325
  • [7] Risk of noncardiac surgery after coronary drug-eluting stent implantation
    Compton, P. Alexander
    Zankar, Ahmad A.
    Adesanya, Adebola O.
    Banerjee, Subhash
    Brilakis, Emmanouil S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (09): : 1212 - 1213
  • [8] Drug-Eluting Stents in Percutaneous Coronary Intervention A Benefit-Risk Assessment
    Byrne, Robert A.
    Sarafoff, Nikolaus
    Kastrati, Adnan
    Schoemig, Albert
    DRUG SAFETY, 2009, 32 (09) : 749 - 770
  • [9] Changes in the use of drug-eluting stents for percutaneous coronary intervention
    Nadar, S.
    Varma, C.
    Millane, T.
    Lip, G.
    Watson, R.
    HEART, 2008, 94 : A34 - A34
  • [10] CHRONIC KIDNEY DISEASE AND THE RISK OF STENT THROMBOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION WITH DRUG-ELUTING STENTS
    Wang Zhijian
    Zhou Yujie
    Zhao Yingxin
    Liu Yuyang
    Shi Dongmei
    Gao Fei
    HEART, 2010, 96 : A157 - A157